Latest News

Dr. Reddy’s Laboratories Announces the Launch of Sevelamer Carbonate for Oral Suspension in the U.S. Market




HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Sevelamer Carbonate for Oral Suspension, in 0.8 g and 2.4 g packets, a therapeutic equivalent generic version of Renvela (sevelamer carbonate) for Oral Suspension, approved by the U.S. Food and Drug Administration (USFDA). The Renvela brand and generic had U.S. sales of approxima

Source link

Related posts

Kotex Tampons Recall: Defect May Cause Vaginal Infection, Reports Say

Newsemia

Dopamine receptor study opens door to targeted treatments for neuropsychiatric disorders

Newsemia

In Sickness and in Health: COVID-Era Weddings

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World